 On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. NASDAQ: STAB, as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets. This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total immune health including autoimmune and inflammatory diseases, such as fibromyalgia and multiple sclerosis, blood disorders like anemia and lupus, even cancer and various other infectious diseases. 